Anthos Therapeutics is led by a world-class executive team highly experienced in the successful development of therapies for CVM disease.
John Glasspool, a former leader of Novartis’ cardiovascular franchise with 30 years of experience in the biopharmaceutical industry, is CEO of Anthos Therapeutics. Mr. Glasspool served as Global Head of Novartis’ Cardiovascular and Metabolic Diseases franchise.
MANAGEMENT TEAM
Dan Bloomfield, M.D
Chief Medical Officer
Debra Freedholm
SVP, Clinical Operations
Erika Dahl, Ph.D.
Program Manager
Mike Doremus
Head of Technical Operations
John Glasspool
CEO
Jonathan Freeman, Ph.D
Co-Founder and Chief Operating Officer
Gi Gi Galiano
Head, Project Management
Janeen Salter
Director of Clinical Operations
Bruce Hug, M.D., Ph.D
Vice President, Clinical Development
Alisha Lundholm, CPA, MSA
Corporate Controller
Drew Young
Chief Commercial Officer and Head of Patient Experience
David McIntyre B.EC., LL.B., CPA, MBA
Chief Financial Officer
Nik Mehta, Ph.D
Chief Technical and Regulatory Officer
Jessica Patrick Seabrook
Office Operations & Events Manager
CONSULTANTS
Connie Cullen, PH.D
Principal Consultant
Yasser Khder, M.D, PH.D
Founder & Senior Consultant at MYRA Life Science Services
BOARD OF DIRECTORS
Scott Beardsley
Ari Brettman, M.D
Raymond Camahort
Mike Exton
Nicholas Galakatos, Ph.D
John Glasspool
CEO